XML 21 R9.htm IDEA: XBRL DOCUMENT
v3.20.2

Goodwill | 6 Months Ended
--- | ---
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill | Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows:
(In thousands) | North American OTC Healthcare |  | International OTC Healthcare |  |  |  | Consolidated
Balance - March 31, 2020 |  |  |  |  |  |  |
| Goodwill | $ | 710,354 |  |  | $ | 28,536 |  |  |  |  | $ | 738,890 |
| Accumulated impairment loss | (163,711) |  |  | — |  |  |  |  | (163,711) |
Balance - March 31, 2020 | 546,643 |  |  | 28,536 |  |  |  |  | 575,179 |
| Effects of foreign currency exchange rates | — |  |  | 2,740 |  |  |  |  | 2,740 |
Balance - September 30, 2020 |  |  |  |  |  |  |
| Goodwill | 710,354 |  |  | 31,276 |  |  |  |  | 741,630 |
| Accumulated impairment loss | (163,711) |  |  | — |  |  |  |  | (163,711) |
Balance - September 30, 2020 | $ | 546,643 |  |  | $ | 31,276 |  |  |  |  | $ | 577,919 |
On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. On February 29, 2020, the date of our annual impairment review, there were no indicators of impairment as a result of the analysis and, accordingly, no impairment charge was taken on our March 31, 2020 financial statements. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 29, 2020 as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increasing competition, changing consumer preferences, technical advances, or reductions in advertising and marketing may require an impairment charge to be recorded in the future. We continuously monitor events which could trigger an interim impairment analysis, which included the impact of COVID-19 for the period ended September 30, 2020. As of September 30, 2020, we determined no events have occurred that would indicate potential impairment of goodwill. However, the continued duration and severity of COVID-19 may result in future impairment charges as the prolonged pandemic could have an impact on our results due to changes in consumer habits. This could result in changes to the assumptions utilized in the annual impairment analysis to determine the estimated fair value of our goodwill, including long-term growth rates and discount rates.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=2144439 + Details
Name: | us-gaap_GoodwillDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration